老年女性晚期乳腺癌卡培他滨节律化疗与常规化疗的临床疗效比较(1)
【摘要】 目的：评价以小剂量卡培他滨持续给药的节律化疗方式与常规化疗方式治疗老年女性晚期乳腺癌的临床疗效和不良反应，了解前者是否存在优势。方法：研究对象为2013年4月-2014年10月本院收治的54例老年女性晚期乳腺癌患者。其中31例给予小剂量卡培他滨的持续给药方式(口服卡培他滨1500 mg/m2，1次/d，连服4周，休息1周，每5周为1个化疗周期)进行治疗，共完成2～12个化疗周期，中位化疗周期数为3个。23例给予卡培他滨单药常规化疗(卡培他滨1250 mg/m2，2次/d，连服2周，休息1周，每3周为1个化疗周期)，共完成2～19个化疗周期，中位化疗周期数为4个。对至少接受过2个化疗周期的患者进行疗效评估。结果：卡培他滨节律化疗组，疾病控制率(DCR)为38.7%(12/31)，中位TTP为3.8个月，中位OS为7.1个月；卡培他滨常规化疗组，疾病控制率(DCR)为39.1%(9/23)，中位TTP为3.0个月，中位OS为7.3个月。两者比较差异均无统计学意义(P>0.05)。卡培他滨节律化疗组，消化系统不良反应、骨髓抑制、手足综合征大多为Ⅰ～Ⅱ度，患者能够很好耐受治疗，中途无需中断治疗。常规化疗组Ⅲ～Ⅳ度毒性反应明显，主要表现在白细胞降低、血小板下降、乏力、手足综合征等。卡培他滨节律化疗组患者生活质量较卡培他滨常规化疗组明显改善，差异有统计学意义(P<0.05)。结论：应用小剂量卡培他滨节律化疗方式治疗老年晚期乳腺癌患者与常规化疗方式比较，对疾病控制及疗效相似，而不良反应较轻，明显提高患者的生活质量，值得作进一步的研究。
, http://www.100md.com
【关键词】 晚期乳腺癌； 节律化疗； 卡培他滨； 老年女性
【Abstract】 Objective：To evaluate the clinical efficacy and adverse reactions between small dose of Capecitabine metronomic chemotherapy of sustained drug delivery method and the conventional mode of chemotherapy in the treatment of elderly female patients with advanced breast cancer，to understand whether the former has advantages.Method：From April 2013 to October 2014，54 elderly female patients with advanced breast cancer admitted to our hospital were selected as the research objects.31 cases were treated with small dose of Capecitabine for sustained drug delivery mode(Capecitabine each oral 1500 mg/m2，once a day，for 4 weeks，then rest for 1 week，every 5 weeks for 1 cycle of chemotherapy) treatment，completed a total of 2 to 12 cycles of chemotherapy，median number of chemotherapy cycles for 3.23 cases were treated with Capecitabine monotherapy (conventional chemotherapy of Capecitabine and 1250 mg/m2，twice a day，for 2 weeks，then rest for 1 week，every 3 weeks for 1 cycle of chemotherapy)，completed a total of 2 to 19 cycles of chemotherapy，the median number of chemotherapy cycles for 4.The efficacy was evaluated on the received at least
, 百拇医药
2 cycles of chemotherapy patients.Result：In Capecitabine metronomic chemotherapy group，the disease control rate(DCR) was 38.7%(12/31)，the median TTP was 3.8 months，the median OS was 7.1 months.In Capecitabine conventional chemotherapy group，the disease control rate(DCR) was 39.1%(9/23)，the median TTP was 3.0 months，the median OS was 7.3 months.There were no statistically significant differences between the two groups(P>0.05).In Capecitabine metronomic chemotherapy group，hand foot syndrome，bone marrow depression，digestive system adverse reactions were at Ⅰ-Ⅱ degree mostly.Patients could tolerate the therapy without stopping drug.In conventional chemotherapy group，the toxicity of Ⅲ-Ⅳ degree were obvious，mainly in the decrease of white blood cell，platelet decrease，fatigue，hand foot syndrome.The life quality of patients in Capecitabine metronomic chemotherapy group was significantly improved than the Capecitabine conventional chemotherapy group，the difference was statistically significant(P<0.05).Conclusion：The application of small dose of Capecitabine metronomic chemotherapy compared with conventional chemotherapy in the treatment of elderly patients with advanced breast cancer，the curative effect to control the progression of the disease is similar，with mild adverse reactions，improve the life quality of patients，it is worthy of further research., http://www.100md.com(蒋琳 谭榜宪 赵妍丽 刘芳 杜国波 侯敏 皈燕 柳弥)
, http://www.100md.com
【关键词】 晚期乳腺癌； 节律化疗； 卡培他滨； 老年女性
【Abstract】 Objective：To evaluate the clinical efficacy and adverse reactions between small dose of Capecitabine metronomic chemotherapy of sustained drug delivery method and the conventional mode of chemotherapy in the treatment of elderly female patients with advanced breast cancer，to understand whether the former has advantages.Method：From April 2013 to October 2014，54 elderly female patients with advanced breast cancer admitted to our hospital were selected as the research objects.31 cases were treated with small dose of Capecitabine for sustained drug delivery mode(Capecitabine each oral 1500 mg/m2，once a day，for 4 weeks，then rest for 1 week，every 5 weeks for 1 cycle of chemotherapy) treatment，completed a total of 2 to 12 cycles of chemotherapy，median number of chemotherapy cycles for 3.23 cases were treated with Capecitabine monotherapy (conventional chemotherapy of Capecitabine and 1250 mg/m2，twice a day，for 2 weeks，then rest for 1 week，every 3 weeks for 1 cycle of chemotherapy)，completed a total of 2 to 19 cycles of chemotherapy，the median number of chemotherapy cycles for 4.The efficacy was evaluated on the received at least
, 百拇医药
2 cycles of chemotherapy patients.Result：In Capecitabine metronomic chemotherapy group，the disease control rate(DCR) was 38.7%(12/31)，the median TTP was 3.8 months，the median OS was 7.1 months.In Capecitabine conventional chemotherapy group，the disease control rate(DCR) was 39.1%(9/23)，the median TTP was 3.0 months，the median OS was 7.3 months.There were no statistically significant differences between the two groups(P>0.05).In Capecitabine metronomic chemotherapy group，hand foot syndrome，bone marrow depression，digestive system adverse reactions were at Ⅰ-Ⅱ degree mostly.Patients could tolerate the therapy without stopping drug.In conventional chemotherapy group，the toxicity of Ⅲ-Ⅳ degree were obvious，mainly in the decrease of white blood cell，platelet decrease，fatigue，hand foot syndrome.The life quality of patients in Capecitabine metronomic chemotherapy group was significantly improved than the Capecitabine conventional chemotherapy group，the difference was statistically significant(P<0.05).Conclusion：The application of small dose of Capecitabine metronomic chemotherapy compared with conventional chemotherapy in the treatment of elderly patients with advanced breast cancer，the curative effect to control the progression of the disease is similar，with mild adverse reactions，improve the life quality of patients，it is worthy of further research., http://www.100md.com(蒋琳 谭榜宪 赵妍丽 刘芳 杜国波 侯敏 皈燕 柳弥)